Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Bju International

Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study

  • Arjun Nathan1,2,3
  • Matthew G. Parry2,3
  • Emily Mayne1,2
  • Adrian Cook2
  • Justin Liu1,2
  • Raghav Varma1,2
  • Will Cuningham1
  • Joanna Dodkins1,2
  • Marina Parry2
  • Julie Nossiter2
  • Ajay Aggarwal1,2,4
  • Jan van der Meulen1,2
2 more authors
  • Alison Tree5
  • Noel Clarke6,7
7 affiliations
  1. 1Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine London UK
  2. 2National Cancer Audit Collaborating Centre Clinical Effectiveness Unit, Royal College of Surgeons of England London UK
  3. 3Department of Surgery and Interventional Science University College London London UK
  4. 4Guy's Cancer Centre Guy's and St Thomas' NHS Foundation Trust London UK
  5. 5Department of Radiology The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research London UK
  6. 6Department of Urology The Christie NHS Foundation Trust Manchester UK
  7. 7Division of Cancer Sciences The University of Manchester Manchester UK
Read full textPDFDOICite

Related

  1. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
    Daniel J. George, Jasmina I. Ivanova, Maëlys Touya +6
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Impact of traditional Chinese medicine combined with conventional therapies on the survival of patients with metastatic prostate cancer: a retrospective observational cohort study.
    Jianfu Zhou, Shuyang Yang, Haoqiang Chen +7
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  3. Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.
    Galip Can Uyar, Kadriye Başkurt, Orhun Akdoğan +8
    The oncologistPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617
    M. J. Lee, L. Yu, N. Zorko +5
    bioRxivPreprintCC BYFull textOncologybioRxiv
  5. Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
    Georges Gebrael, Yeonjung Jo, Varun Nandakumar +14
    JAMA network openPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{nathan2026improved,
  title = {{Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study}},
  author = {Arjun Nathan and Matthew G. Parry and Emily Mayne and Adrian Cook and Justin Liu and Raghav Varma and Will Cuningham and Joanna Dodkins and Marina Parry and Julie Nossiter and Ajay Aggarwal and Jan van der Meulen and Alison Tree and Noel Clarke},
  journal = {Bju International},
  year = {2026},
  month = oct,
  doi = {10.1111/bju.70432},
  url = {https://doi.org/10.1111/bju.70432},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study
AU  - Arjun Nathan
AU  - Matthew G. Parry
AU  - Emily Mayne
AU  - Adrian Cook
AU  - Justin Liu
AU  - Raghav Varma
AU  - Will Cuningham
AU  - Joanna Dodkins
AU  - Marina Parry
AU  - Julie Nossiter
AU  - Ajay Aggarwal
AU  - Jan van der Meulen
AU  - Alison Tree
AU  - Noel Clarke
PY  - 2026
DA  - 2026/10/08
JO  - Bju International
DO  - 10.1111/bju.70432
UR  - https://doi.org/10.1111/bju.70432
SN  - 1464-4096
SN  - 1464-410X
ER  -